Biochem/physiol Actions

Cell permeable: no

Reversible: yes

Product competes with ATP.

Primary Target p56^lck

Target IC₅₀: 4 nM, 5 nM, 5 nM, 100 nM, against p56lck, p59fynT, Hck, and Src, respectively; 600 nM against anti-CD3-stimulated tyrosine phosphorylation of human T cells

General description

A potent, reversible, ATP-competitive, and selective inhibitor of the src family of tyrosine kinases that is similar to PP1. Selectively inhibits p56^lck (IC₅₀ = 4 nM), p59^fynT (IC₅₀ = 5 nM), Hck (IC₅₀ = 5 nM), and Src (IC₅₀ = 100 nM) compared to other tyrosine kinases, such as EGF-R (IC₅₀ = 480 nM), JAK2 (IC₅₀ >50 µM) or ZAP-70 (IC₅₀ >100 µM). Also potently inhibits anti-CD3-stimulated tyrosine phosphorylation of human T cells (IC₅₀ = 600 nM).

A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. Inhibits p56^lck (IC₅₀ = 4 nM), p59^fynT (IC₅₀ = 5 nM), Hck (IC₅₀ = 5 nM), and Src (IC₅₀ = 100 nM). Does not significantly affect the activity of EGFR kinase (IC₅₀ = 480 nM), JAK2 (IC₅₀ >50 µM), or ZAP-70 (IC₅₀ >100 µM). Inhibits the activation of focal adhesion kinase and its phosphorylation at Tyr⁵⁷⁷. Also potently inhibits anti-CD3-stimulated tyrosine phosphorylation of human T cells (IC₅₀ = 600 nM). A 10 mM (1 mg/331 µl) solution of PP2 (Cat. No. 529576) in DMSO also available.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Karni, R., et al. 2003. FEBS Lett.537, 47.Salazar, E.P., and Rozengurt, E. 1999. J. Biol. Chem. 274, 28371.Hanke, J.H., et al. 1996. J. Biol. Chem.271, 695.Selected CitationsLee, J., et al. 2009. Cell Stem Cell5, 76.

Packaging

1 mg in Plastic ampoule

5 mg in Glass bottle

Packaged under inert gas

Preparation Note

Further dilute with aqueous buffers just prior to use.

Warning

Toxicity: Standard Handling (A)